clinical trial · NCT05980806
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild ThrombocytopeniaSelinexor 60 mgSelinexor 40 mgRuxolitinibPacritinibMomelotinib
brief summary
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
started
Apr 22, 2024
primary completion
Jun 1, 2027
completion
Oct 1, 2028
last updated
Feb 12, 2026
official title
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol